Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3P-Y058-739 in Advanced Solid Tumors
NCT05120596Phase 2Recruiting
- Sponsor
- T3 Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Microbiome Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of T3P-Y058-739 in solid tumor (3 arms), sponsored by T3 Pharmaceuticals. Primary endpoints: Safety and Recommended Phase II Dose up to 45 months and Safety and Preliminary Antitumor Response up to 45 months. Started Apr 2022; status: recruiting.
02
Drugs
T3P-Y058-739
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05120596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120596.